| Literature DB >> 35448147 |
Cuong Hung Luu1, Giang Nguyen1, Thanh-Tuyen Le1, Thanh-Mai Ngoc Nguyen1, V H Giang Phan1, Mohanapriya Murugesan2, Ramya Mathiyalagan2, Lu Jing3, Gopinathan Janarthanan4, Deok Chun Yang2, Yi Li5, Thavasyappan Thambi6.
Abstract
In pain relief, lidocaine has gained more attention as a local anesthetic. However, there are several side effects that limit the use of local anesthetics. Therefore, it is hypothesized that a hydrogel system with facile design can be used for prolonged release of lidocaine. In this study, we developed a formulation comprises of sodium alginate (SA) and graphene oxide (GO) to prolong the release of lidocaine. The gelation was induced by physically crosslinking the alginate with Ca2+ ions. The formation of blank SA and GO-reinforced SA hydrogels was investigated with different concentration of Ca2+ ions. The controlled release of lidocaine hydrochloride (LH) on both hydrogel systems was studied in PBS solution. The GO-reinforced SA hydrogels exhibited more sustained release than SA hydrogels without GO. In vitro biocompatibility test in L929 fibroblast cells confirmed the non-toxic property of hydrogels. Furthermore, to prove the in-situ gelation and biodegradability of hydrogels the hydrogels were injected on mice model and confirmed the stable gel formation. The hydrogels implanted onto the subcutaneous tissue of hydrogels retained over one week. These results indicate that LH-loaded GO-reinforced SA hydrogel can be a potential biomaterial for controlled release of local anesthetics.Entities:
Keywords: alginate; graphene oxide; injectable hydrogel; lidocaine; local anesthesia
Year: 2022 PMID: 35448147 PMCID: PMC9026710 DOI: 10.3390/gels8040246
Source DB: PubMed Journal: Gels ISSN: 2310-2861
Scheme 1Illustrative models of GO-SA hydrogel physically crosslinked by divalent Ca2+ cations for LH delivery.
Figure 1(A) Fourier-transform infrared (FTIR) spectra and (B) Thermogravimetric analysis of GO2 (red line), GO4 (blue line), GO6 (black line) and graphite (square dotted line); (C,D) Scanning electron microscopic (SEM) images of GO6 dispersed in deionized water solution.
Figure 2(A) Solubility of graphite and GOs after 12 h dispersed in deionized water. (B) Solubility of GO6 after 12 h dispersed in surfactant and salt. (C) Investigation of ion complexes formulation of graphene oxide and lidocaine hydrochloride.
Gelation time of GO-free and GO-integrated SA hydrogels. Gelation time recorded in seconds.
| Ca2+ Concentration (mol/L) | |||||||
|---|---|---|---|---|---|---|---|
| 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | |
|
| No gel formation | 71.7 ± 1.5 | 65.3 ± 1.2 | 49.0 ± 1.0 | 32.7 ± 2.1 | ||
|
| No gel formation | 61.7 ± 0.6 | 52.3 ± 0.6 | 41.7 ± 1.2 | 30.3 ± 1.5 | ||
Figure 3(A) Macroscopic images of hydrogel development. The experiment was conducted with blank SA hydrogel and GO-SA hydrogel. Both hydrogel systems commenced forming hydrogel at the feeding concentration of crosslinker of 0.04 mol/L, which zoning within a dotted area. SEM images of (B) SA and (C) GO-SA hydrogels.
Figure 4Degradation of SA and GO-SA hydrogels in PBS.
Figure 5The in vitro lidocaine hydrochloride release profiles of SA and GO-SA systems in PBS solution. The error bars in the graph represent standard deviations (n = 4).
Figure 6The in vitro cell viability of L929 mouse fibroblast cells exposed with different concentration of SA and GO-SA hydrogels. The error bars in the graph represent standard deviations (n = 4).
Figure 7Photographs of the in vivo study: (A) Grey bumps of GO-SA hydrogel cured under the mice’s skin after hypodermic injection, (B) Incision to test stable gel formation of the hydrogel. (C) After a week, the hydrogel remained stable without inflammation and (D) After 1 week, disintegration of the GO-SA hydrogels was observed. This is mainly due to the slow exchange of cations and salt effects.
The compositions of hydrogel samples before testing aqueous degradation.
| Sample No | GO6 (mL) | SA 8% (mL) | LH 2% (mL) | Ca2+ (0.06M) (mL) | PBS (mL) |
|---|---|---|---|---|---|
|
| 0.5 (0%) | 0.5 | 0.5 | 0.5 | 3.0 |
|
| 0.5 (0.125%) | 0.5 | 0.5 | 0.5 | 3.0 |
|
| 0.5 (0.250%) | 0.5 | 0.5 | 0.5 | 3.0 |
|
| 0.5 (0.500%) | 0.5 | 0.5 | 0.5 | 3.0 |